CVS Health Co. (NYSE:CVS) Shares Sold by Pathstone Holdings LLC

Pathstone Holdings LLC lowered its holdings in CVS Health Co. (NYSE:CVS - Free Report) by 14.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 189,874 shares of the pharmacy operator's stock after selling 32,411 shares during the quarter. Pathstone Holdings LLC's holdings in CVS Health were worth $8,526,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of CVS. Park Avenue Securities LLC boosted its holdings in CVS Health by 5.8% in the 4th quarter. Park Avenue Securities LLC now owns 24,646 shares of the pharmacy operator's stock valued at $1,106,000 after purchasing an additional 1,359 shares during the last quarter. Empirical Asset Management LLC grew its holdings in CVS Health by 816.4% during the 4th quarter. Empirical Asset Management LLC now owns 36,885 shares of the pharmacy operator's stock worth $1,656,000 after acquiring an additional 32,860 shares in the last quarter. Sterling Financial Group Inc. boosted its holdings in CVS Health by 16.4% in the fourth quarter. Sterling Financial Group Inc. now owns 15,363 shares of the pharmacy operator's stock valued at $690,000 after purchasing an additional 2,169 shares in the last quarter. Avanza Fonder AB acquired a new position in CVS Health during the fourth quarter worth approximately $4,745,000. Finally, HB Wealth Management LLC raised its stake in shares of CVS Health by 12.7% during the fourth quarter. HB Wealth Management LLC now owns 20,029 shares of the pharmacy operator's stock worth $899,000 after purchasing an additional 2,262 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Trading Up 1.5%

CVS stock traded up $0.95 during midday trading on Tuesday, hitting $63.73. The company had a trading volume of 7,394,444 shares, compared to its average volume of 11,411,869. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. The stock has a market cap of $80.62 billion, a price-to-earnings ratio of 17.41, a PEG ratio of 0.98 and a beta of 0.60. CVS Health Co. has a 52 week low of $43.56 and a 52 week high of $72.51. The stock's 50 day moving average price is $66.52 and its 200 day moving average price is $59.29.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. The business had revenue of $94.59 billion during the quarter, compared to analysts' expectations of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The firm's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.31 earnings per share. As a group, equities research analysts expect that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were paid a $0.665 dividend. The ex-dividend date was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.17%. CVS Health's payout ratio is currently 63.48%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CVS. Morgan Stanley restated an "overweight" rating on shares of CVS Health in a report on Tuesday, April 15th. Barclays lifted their price objective on CVS Health from $73.00 to $82.00 and gave the stock an "overweight" rating in a report on Friday, May 2nd. Evercore ISI lifted their price target on CVS Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a research note on Monday, January 27th. Wolfe Research boosted their price objective on CVS Health from 67.00 to 70.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Finally, StockNews.com raised CVS Health from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Three equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, CVS Health currently has an average rating of "Moderate Buy" and a consensus price target of $74.94.

Insider Buying and Selling

In related news, SVP James David Clark sold 7,513 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares in the company, valued at $556,941.90. This represents a 47.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 1.22% of the stock is owned by corporate insiders.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.